A center of excellence focused on clinical research and the marketing of essential prescription drugs, Teva Canada Innovation, headquartered in Montreal, plays a key role in the management of many diseases. Our vision: to improve the health of Canadians through the quality of our people, the benefits of our products and our emphasis on innovation.
Although its legacy spans more than a century, Teva Canada Innovation was founded in 1997 under the name of Teva Marion Partners Canada.
In 2001, Teva Marion Partners Canada became Teva Neuroscience Canada, a wholly-owned division of Teva Pharmaceutical Industries. Teva Neuroscience Canada was then mandated to market and promote innovative neurological medications. The first of those was Copaxone®, a unique treatment against multiple sclerosis. Driven by the sales of this flagship product, the Canadian innovative division of Teva has seen strong and continuous growth.
In April of 2010, the company adopted a new designation: Teva Canada Innovation, which better reflects its desire to expand its activities into new treatment areas and provide a broader and deeper dimension to its vision of providing Canadians with treatment options that ensure a more independent and rewarding life.
A division of Teva Pharmaceutical Industries Ltd., Teva Canada Innovation develops and markets innovative products in Canada.
For more information, visit Teva Canada Innovation’s website at: tevacanadainnovation.com.